Table 1.
Clinical trial EVs-based therapeutics for the treatment of COVID-19.
| EVs source | Administration route | Number of participants | Outcome measurement | Reference | Developmental status |
|---|---|---|---|---|---|
| Mesenchymal stem cell | Inhalation | 30 | Adverse reaction, Time to Clinical Recovery, blood oxygen saturation, level of inflammatory markers | NCT04491240 | Phase I and II |
| Mesenchymal stem cell | Inhalation | 24 | Adverse reactions, Time to Clinical Recovery, level of inflammatory markers | NCT04276987 | Phase I |
| Mesenchymal stem cell | Inhalation | 90 | Adverse reaction, Time to Clinical Recovery, blood oxygen saturation, level of inflammatory markers | NCT04602442 | Phase II |
| Bone Marrow Mesenchymal Stem Cell | Intravenous infusion | 120 | Time to Clinical Recovery, Neutrophil count, level of inflammatory markers | NCT04493242 | Phase II |
| Unavailable | inhalation | 155 | blood oxygen saturation, level of inflammatory markers | NCT04969172 | Phase II |
| T-RExTM-293 cells | inhalation | 35 | Adverse reaction, Time to Clinical Recovery, blood oxygen saturation, level of inflammatory markers | NCT04747574 | Phase I |
| T cells | inhalation | 60 | Adverse reaction, Time to Clinical Recovery | NCT04389385 | Phase I |
| Placental Mesenchymal Stem Cell | Intravenous infusion | 64 | Adverse reaction, Time to Clinical Recovery, blood oxygen saturation | ISRCTN33578935 | Phase II |